Search
Advanced Search
My Cart

Mitomycin C

SKU
M-1108
  • CAS:50-07-7
  • Formula:C15H18N4O5
  • MW:334.3 Da
  • Appearance:Blue-violet solid
  • Purity:≥99%

3

0

0

SDS
CofA
Product Name Qty
Mitomycin C
2 mg
$37.87
Mitomycin C
5 mg
$54.11
Mitomycin C
10 mg
$91.98
Mitomycin C
100 mg
$638.44
Add to Compare Email
Loading...

Mitomycin C is produced by a strain of actinomyces, Streptomyces caespitosus. It contains three anticancer moieties, quinine, urethane, and aziridine groups. It is used to generate mitotically inactive feeder cells in cell culture systems, such as the mitotically inactive fibroblasts used in embryonic stem cell systems. 

This product is an alkylating agent that specifically targets the guanine nucleoside sequence 5′-CpG-3′. It inhibits DNA synthesis by covalently reacting with DNA, forming crosslinks between complementary strands of DNA. This interaction prevents separation of complementary DNA strands, inhibiting DNA replication.

Mitomycin C has strong antitumor activity, especially against Ehrlich ascites tumor cells, and strong bactericidal action against gram-positive and gram-negative bacteria. Mitomycin c role in pluripotent stem cells research expands into the CRISPR/Cas9 revolution to permit efficient gene correction.

 

More Information
Alternate Name/Synonyms
Mutamycin; Ametycin; Mitocin-C; Mito-C; MMC
SKU
M-1108
CAS #
50-07-7
Chemical Name
[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
Chemical Formula
C15H18N4O5
Molecular Weight
334.3 Da
Appearance
Blue-violet solid
Purity
≥99%
Solubility
Clear blue-violet solution at 10 mg/mL in DMSO or CH3OH
Melting Point
N/A
Preparation
N/A
Storage Temp
-20°C, desiccated
THERAPEUTIC AREA
Oncological Disorders
USE
Mitomycin C is part of a family of azidine natural products. It is a DNA crosslinking and damaging agent, making it a useful antibiotic and antitumor compound. When crosslinking, Mitomycin C displays absolute specificity and high efficiency for the CpG sequence. Mammalian Cells treated with Mitomycin C (0.4 mg/mL for 5 min) can undergo apoptosis through upregulation of Bad, Fas, FasL and phosphorylated p53 along with activation of caspase-3, caspase-8, and caspase-9 activating both the intrinsic and extrinsic pathway for apoptosis.
MDL NUMBER
MFCD00078109
CHEMACX
X1004059-0
INCHI
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
SMILES
CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
RTECS
CN0700000
UN #'S
UN 2811
PACKING GROUP
II
Handling
Use only in area provided with appropriate exhaust ventilation. Keep away from heat and source of ignition. Empty containers pose a fire risk, evaporate residue under fume hood. Ground all equipment containing material. Do not breathe dust.
Special Shipping
Yes
msds 1
M-1108, Mitomycin C, SDS, diamond format.pdf
Certificate of Analysis 1
M-1108, H1358A.pdf
Certificate of Analysis 2
M-1108, H1184D.pdf
Certificate of Analysis 3
M-1108, H1184C.pdf
GHS PICTOGRAMS
Handling Use only in area provided with appropriate exhaust ventilation. Keep away from heat and source of ignition. Empty containers pose a fire risk, evaporate residue under fume hood. Ground all equipment containing material. Do not breathe dust.
UN #'S UN 2811
Packing Group II
Citations Optogenetic control of endogenous Ca(2+) channels in vivo
Incomplete prophage tolerance by type III-A CRISPR-Cas systems reduces the fitness of lysogenic hosts
A novel family of integrases associated with prophages and genomic islands integrated within the tRNA-dihydrouridine synthase A (dusA) gene
Selective blockade of NF-kappaB by novel mutated IkappaBalpha suppresses CD3/CD28-induced activation of memory CD4+ T cells in asthma
Structure elucidation of DNA interstrand cross-link by a combination of nuclease P1 digestion with mass spectrometry
Long-term, feeder-free maintenance of human embryonic stem cells by mussel-inspired adhesive heparin and collagen type I
MHC mismatch results in neural progenitor cell rejection following spinal cord transplantation in a model of viral-induced demyelination
Dual modulation of the mitochondrial permeability transition pore and redox signaling synergistically promotes cardiomyocyte differentiation from pluripotent stem cells
Generation of PDGFRα+ Cardioblasts from Pluripotent Stem Cells
Mitochondrial Respiratory Defect Causes Dysfunctional Lactate Turnover via AMP-activated Protein Kinase Activation in Human-induced Pluripotent Stem Cell-derived Hepatocytes
Dynamic self-organization of microwell-aggregated cellular mixtures
Chromosome replication and segregation govern the biogenesis and inheritance of inorganic polyphosphate granules
Malfunction in Mitochondrial β-Oxidation Contributes to Lipid Accumulation in Hepatocyte-Like Cells Derived from Citrin Deficiency-Induced Pluripotent Stem Cells
T cell mediated suppression of neurotropic coronavirus replication in neural precursor cells
Impaired Osteogenesis of Disease-Specific Induced Pluripotent Stem Cells Derived from a CFC Syndrome Patient
Tandem mass spectrometry for the determination of the sites of DNA interstrand cross-link
Regenerative potential of mouse embryonic stem cell-derived PDGFRα+ cardiac lineage committed cells in infarcted myocardium
Islet-like organoids derived from human pluripotent stem cells efficiently function in the glucose responsiveness in vitro and in vivo
Impaired osteogenesis in Menkes disease-derived induced pluripotent stem cells
Engraftment of syngeneic and allogeneic endothelial cells, hepatocytes and cholangiocytes into partially hepatectomized rats previously treated with mitomycin C
Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder
We found other products you might like!
To Top